185 related articles for article (PubMed ID: 36681756)
1. Therapeutic beta-lactam dosages and broad-spectrum antibiotics are associated with reductions in microbial richness and diversity in persons with cystic fibrosis.
Hahn A; Burrell A; Chaney H; Sami I; Koumbourlis AC; Freishtat RJ; Crandall KA; Zemanick ET
Sci Rep; 2023 Jan; 13(1):1217. PubMed ID: 36681756
[TBL] [Abstract][Full Text] [Related]
2. Importance of beta-lactam pharmacokinetics and pharmacodynamics on the recovery of microbial diversity in the airway of persons with cystic fibrosis.
Hahn A; Burrell A; Chaney H; Sami I; Koumbourlis AC; Freishtat RJ; Zemanick ET; Louie S; Crandall KA
J Investig Med; 2021 Oct; 69(7):1350-1359. PubMed ID: 34021052
[TBL] [Abstract][Full Text] [Related]
3. Changes in microbiome diversity following beta-lactam antibiotic treatment are associated with therapeutic versus subtherapeutic antibiotic exposure in cystic fibrosis.
Hahn A; Fanous H; Jensen C; Chaney H; Sami I; Perez GF; Koumbourlis AC; Louie S; Bost JE; van den Anker JN; Freishtat RJ; Zemanick ET; Crandall KA
Sci Rep; 2019 Feb; 9(1):2534. PubMed ID: 30796252
[TBL] [Abstract][Full Text] [Related]
4. Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations.
Cogen JD; Faino AV; Onchiri F; Hoffman LR; Kronman MP; Nichols DP; Rosenfeld M; Gibson RL
Clin Infect Dis; 2021 Nov; 73(9):1589-1596. PubMed ID: 34100912
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic Regimen Changes during Cystic Fibrosis Pediatric Pulmonary Exacerbation Treatment.
Cogen JD; Sanders DB; Slaven JE; Faino AV; Somayaji R; Gibson RL; Hoffman LR; Ren CL
Ann Am Thorac Soc; 2023 Sep; 20(9):1293-1298. PubMed ID: 37327485
[No Abstract] [Full Text] [Related]
6. Outcomes of cystic fibrosis pulmonary exacerbations treated with antibiotics with activity against anaerobic bacteria.
Castner LM; Zimbric M; Cahalan S; Powell C; Caverly LJ
J Cyst Fibros; 2021 Nov; 20(6):926-931. PubMed ID: 33612403
[TBL] [Abstract][Full Text] [Related]
7. Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis.
Wagener JS; VanDevanter DR; Konstan MW; Pasta DJ; Millar SJ; Morgan WJ
Pediatr Pulmonol; 2020 Mar; 55(3):828-834. PubMed ID: 31746561
[TBL] [Abstract][Full Text] [Related]
8. The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis.
VanDevanter EJ; Heltshe SL; Skalland M; Lechtzin N; Nichols D; Goss CH
J Cyst Fibros; 2021 Nov; 20(6):932-936. PubMed ID: 33685776
[TBL] [Abstract][Full Text] [Related]
9. Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis.
McElvaney OJ; Heltshe SL; Odem-Davis K; West NE; Sanders DB; Fogarty B; VanDevanter DR; Flume PA; Goss CH
Ann Am Thorac Soc; 2024 May; 21(5):716-726. PubMed ID: 38096105
[No Abstract] [Full Text] [Related]
10. Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations.
Cogen JD; Faino AV; Onchiri F; Hoffman LR; Kronman MP; Nelson M; Nichols DP; Rosenfeld M; VanDevanter DR; Gibson RL
Ann Am Thorac Soc; 2020 Dec; 17(12):1590-1598. PubMed ID: 32726564
[No Abstract] [Full Text] [Related]
11. Using metabolic potential within the airway microbiome as predictors of clinical state in persons with cystic fibrosis.
Shumyatsky G; Burrell A; Chaney H; Sami I; Koumbourlis AC; Freishtat RJ; Crandall KA; Zemanick ET; Hahn A
Front Med (Lausanne); 2022; 9():1082125. PubMed ID: 36698799
[TBL] [Abstract][Full Text] [Related]
12. Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations.
Davis CS; Faino AV; Onchiri F; Gibson RL; Merjaneh L; Ramsey BW; Rosenfeld M; Cogen JD
Ann Am Thorac Soc; 2023 Jan; 20(1):75-82. PubMed ID: 36044723
[No Abstract] [Full Text] [Related]
13. Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis.
Hoppe JE; Wagner BD; Accurso FJ; Zemanick ET; Sagel SD
J Cyst Fibros; 2018 Nov; 17(6):760-768. PubMed ID: 29921503
[TBL] [Abstract][Full Text] [Related]
14. Impact of Antibiotics on the Lung Microbiome and Lung Function in Children With Cystic Fibrosis 1 Year After Hospitalization for an Initial Pulmonary Exacerbation.
Inam Z; Felton E; Burrell A; Chaney H; Sami I; Koumbourlis AC; Freishtat RJ; Zemanick ET; Crandall KA; Hahn A
Open Forum Infect Dis; 2022 Sep; 9(9):ofac466. PubMed ID: 36168550
[TBL] [Abstract][Full Text] [Related]
15. Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response.
Lam JC; Somayaji R; Surette MG; Rabin HR; Parkins MD
BMC Infect Dis; 2015 Mar; 15():145. PubMed ID: 25887462
[TBL] [Abstract][Full Text] [Related]
16. Polymicrobial infections and antibiotic treatment patterns for cystic fibrosis pulmonary exacerbations.
Faino AV; Hoffman LR; Gibson RL; Kronman MP; Nichols DP; Rosenfeld M; Cogen JD
J Cyst Fibros; 2023 Jul; 22(4):630-635. PubMed ID: 36849332
[TBL] [Abstract][Full Text] [Related]
17. Impact of Anaerobic Antibacterial Spectrum on Cystic Fibrosis Airway Microbiome Diversity and Pulmonary Function.
Bozzella MJ; Chaney H; Sami I; Koumbourlis A; Bost JE; Zemanick ET; Freishtat RJ; Crandall KA; Hahn A
Pediatr Infect Dis J; 2021 Nov; 40(11):962-968. PubMed ID: 34269323
[TBL] [Abstract][Full Text] [Related]
18. Measuring the impact of an empiric antibiotic algorithm for pulmonary exacerbation in children and young adults with cystic fibrosis.
Kennedy C; Greenberg I; Perez GF; Chaney H; Sami I; Ogunlesi F; Koumbourlis AC; Hammer B; Hamdy RF; Cogen JD; Payne AS; Hahn A
Pediatr Pulmonol; 2022 Apr; 57(4):965-975. PubMed ID: 35084122
[TBL] [Abstract][Full Text] [Related]
19. Sweat metabolomics before and after intravenous antibiotics for pulmonary exacerbation in people with cystic fibrosis.
Woodley FW; Gecili E; Szczesniak RD; Shrestha CL; Nemastil CJ; Kopp BT; Hayes D
Respir Med; 2022 Jan; 191():106687. PubMed ID: 34864373
[TBL] [Abstract][Full Text] [Related]
20. Clinical Outcomes of Antipseudomonal versus Other Antibiotics among Children with Cystic Fibrosis without
Cogen JD; Faino AV; Onchiri F; Gibson RL; Hoffman LR; Nichols DP; Rosenfeld M; Kronman MP
Ann Am Thorac Soc; 2022 Aug; 19(8):1320-1327. PubMed ID: 35289740
[No Abstract] [Full Text] [Related]
[Next] [New Search]
